Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash & Current Investments (2022 - 2025)

Historic Cash & Current Investments for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Addex Therapeutics' Cash & Current Investments fell 2915.3% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 2915.3%. This contributed to the annual value of $3.8 million for FY2024, which is 1159.12% down from last year.
  • Latest data reveals that Addex Therapeutics reported Cash & Current Investments of $2.7 million as of Q3 2025, which was down 2915.3% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Addex Therapeutics' Cash & Current Investments peaked at $22.2 million during Q1 2022, and registered a low of $490.17 during Q3 2023.
  • Over the past 4 years, Addex Therapeutics' median Cash & Current Investments value was $3.9 million (recorded in 2024), while the average stood at $6.8 million.
  • As far as peak fluctuations go, Addex Therapeutics' Cash & Current Investments crashed by 9999.77% in 2023, and later surged by 78969326.74% in 2024.
  • Quarter analysis of 4 years shows Addex Therapeutics' Cash & Current Investments stood at $7.2 million in 2022, then tumbled by 39.67% to $4.4 million in 2023, then decreased by 12.31% to $3.8 million in 2024, then dropped by 28.24% to $2.7 million in 2025.
  • Its Cash & Current Investments stands at $2.7 million for Q3 2025, versus $2.8 million for Q2 2025 and $7598.2 for Q1 2025.